Medifast(US:MED)2024-02-21 00:27Financial Performance (Q4 2023) - Revenue for Q4 2023 was within the guidance range[2] - Gross margin for Q4 2023 was 740%[6] - Medifast had $150 million in cash and cash equivalents and investments[8, 25] - Revenue was $1072 million[9] - GAAP diluted EPS was $910, while adjusted diluted EPS was $964[9] Financial Performance (FY 2023) - Revenue was $191 million[26] - GAAP diluted EPS was $055, while adjusted diluted EPS was $109[26] - Gross profit as a percentage of sales was 724%[27] - Operating cash flow was $148 million[28] Strategic Initiatives - Dividend was discontinued to redirect capital to customer acquisition and experience through marketing and technology[11] - Collaboration with LifeMD to target the medically supported weight loss market[6]